Aspiration pneumonia affects 74.8% of head and neck cancer patients after chemoradiotherapy
This supplementary analysis of a phase II/III trial evaluated the incidence and risk factors of aspiration pneumonia (AP) in patients with resected high-risk head and neck cancer undergoing postoperative chemoradiotherapy (POCRT) in a multicenter setting in Japan. Of 251 patients, 100 who underwent laryngectomy were excluded, leaving 151 for analysis.
During POCRT, 93 of 151 patients (61.6%) developed AP; after POCRT, 85 of 151 (56.3%) developed AP; overall, 113 of 151 (74.8%) developed AP. Independent risk factors for AP included dysphagia ≥ grade 3 during CRT (odds ratio 4.691, p = 0.0009) and reconstruction surgery (odds ratio 2.859, p = 0.0061).
Despite the high incidence, AP was not significantly associated with overall survival, relapse-free survival, or local relapse-free survival. Safety data focused on AP incidence; serious adverse events, discontinuations, and tolerability were not reported.
Limitations include the post-hoc nature of the analysis, exclusion of laryngectomy patients, and single-country setting (Japan). Confidence intervals for odds ratios were not reported. Clinicians should recognize that while AP is common after POCRT, its occurrence does not appear to affect survival outcomes in this cohort.